Rigel Pharmaceuticals, Inc. (RIGL) Q2 FY26 Earnings Call

Vepanu’s August launch is Rigel’s principal near-term growth catalyst, but management is withholding guidance until sales establish a trajectory.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-04
Length55 minutes
EPS$0.88
EPS consensus$0.91
Revenue$78.7M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All RIGL earnings · Back to RIGL overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.